UroGen Pharma vs Zymeworks
UroGen Pharma reported revenue of $110 million in fiscal 2025, about the same as Zymeworks' $106 million in fiscal 2025. UroGen Pharma's revenue grew 21.4% in its latest year, and Zymeworks' grew 38.9%. UroGen Pharma had an operating margin of -113.7%, against -87.3% at Zymeworks. Free cash flow was −$163 million at UroGen Pharma and −$35 million at Zymeworks.
Side by side
| UroGen Pharma | Zymeworks | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $110M | $106M |
| Revenue growth | 21.4% | 38.9% |
| Revenue growth a year, last 5 years | 56.2% | 22.1% |
| Gross margin | 88.7% | — |
| Operating margin | −113.7% | −87.3% |
| Net margin | −139.8% | −76.6% |
| Free cash flow | −$163M | −$35M |
| Free cash flow margin | −148.2% | −32.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $42M |
| Change in diluted share count | 12.2% | −0.6% |
| Last close | $26.18 | $26.24 |
| P/E at the last close | — | 50.5× |
| Insider trades, last 12 months | sold $4.7 million | sold $4.7 million |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
UroGen PharmaZymeworks
Operating margin
Percent of revenue
UroGen PharmaZymeworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
UroGen PharmaZymeworks
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the UroGen Pharma and Zymeworks pages.